MedWatch

Novo advances third business leg with Ventus deal, says analyst

According to a Sydbank analyst, the recent agreement with Ventus is a sign that Novo Nordisk is betting on a newer area, chronic diseases.

Photo: Niels Hougaard

Novo Nordisk, known for making medicines for diabetes and bleeding disorders, has continued its foray into chronic diseases by striking an agreement with Ventus Therapeutics, a US-based biotech focused on using small molecules to treat challenging targets.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs